The primary objective is to assess the change of HbA1c level from baseline after a 6-month follow up among uncontrolled patients with T2D who will be initiated to Diamicron® MR 60 (originator product) plus an educational program (NGAYDAUTIEN) as monotherapy or in add on to metformin in comparison to an initiation of an Oral Antidiabetic Drug (OAD) (except Diamicron®) as monotherapy or in add on to metformin.
Study Type
OBSERVATIONAL
Enrollment
678
Servier Affaires Médicales
Suresnes, France
change of HbA1c level (measured in %) from baseline after a 6-month follow-up among the 2 arms
Time frame: from baseline to 6-month follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.